Table 2 Mortality and immuno-virological status at 5 years (+/−3 months) of children with antiretroviral treatment initiated within the first year of life (ANRS-Pediacam Study, 2008–2013, Cameroon) (N = 149)
| Viral load at 2 years (+/− 3 months) of antiretroviral treatment initiation | ||||||||
|---|---|---|---|---|---|---|---|---|
|
All N = 149 |
< 4 00 copies/mL N = 90 |
≥ 400 copies/mL N = 44 |
Absence of viral load N = 15 | |||||
| N | % | N | % | N | % | N | % | |
| Death between 2 and 5 years of ART initiation | ||||||||
| Yes | 5 | 3.4 | 0 | 0.0 | 2 | 8.5 | 3 | 20.0 |
| No | 144 | 94.6 | 90 | 100.0 | 42 | 91.5 | 12 | 80.0 |
| Virological status at 5 years (+/−3 months) after ART initiation | ||||||||
| VL < 400 copies/mL | 99 | 66.4 | 68 | 75.6 | 28 | 63.6 | 3 | 20.0 |
| VL ≥ 400 copies/mL | 22 | 14.8 | 9 | 10.0 | 12 | 27.3 | 1 | 6.7 |
| Absence of VL if not dead at M60 | 23 | 15.4 | 13 | 14.4 | 2 | 4.6 | 8 | 53.3 |
| Probability at 5 years (+/−3 months) after ART initiation, using Kaplan-Meier estimation method | ||||||||
| Of maintaining virological success (Group 1) | 90 | 64.0 (30 events) | ||||||
| Of achieving at least once VL < 400 copies/mL (Group 2) | 44 | 76.0 (30 events) | ||||||
| CD4 percentage at 5 years of ART initiation | ||||||||
| < 15 | 1 | 0.7 | 0 | 0.0 | 1 | 2.3 | 0 | 0.0 |
| [15–20[ | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| [20–25[ | 7 | 4.7 | 5 | 5.6 | 1 | 2.3 | 1 | 6.7 |
| ≥ 25 | 115 | 77.2 | 74 | 82.2 | 38 | 63.6 | 3 | 20.0 |
| Not measured if not dead at M60 | 21 | 14.1 | 11 | 12.2 | 2 | 4.6 | 8 | 53.3 |